FDA Advances NRx Pharmaceuticals’ Ketamine Treatment for Severe Mental Illness

The U.S. Food and Drug Administration has provided positive feedback on NRx Pharmaceuticals’ application for a ketamine-based treatment for severe mental illness, moving the potential therapy closer to approval. The company announced receipt of a positive Discipline Review Letter from the FDA Office of Generic Drugs covering quality-related aspects of its ketamine Abbreviated New Drug Application (ANDA), with only minor administrative updates requested.

This regulatory progress supports expectations for potential approval of NRx’s preservative-free ketamine product in summer 2026. The company also reported a supportive meeting with FDA leadership that aligned with federal priorities to accelerate treatments for severe mental illness. The treatment, designated NRX-100, has received Fast Track Designation for addressing suicidal ideation in depression, including bipolar depression.

NRx Pharmaceuticals is developing therapeutics based on its NMDA platform for central nervous system disorders, specifically targeting suicidal depression, chronic pain, and PTSD. The company’s pipeline includes both NRX-100 (preservative-free intravenous ketamine) and NRX-101 (oral D-cycloserine/lurasidone). NRX-101 has been awarded Breakthrough Therapy Designation for treating suicidal bipolar depression.

The company has filed an Abbreviated New Drug Application and initiated a New Drug Application filing for NRX-100 with an application for the Commissioner’s National Priority Voucher Program. This program focuses on treatments for suicidal ideation in patients with depression, including bipolar depression. More information about the company’s developments is available through its corporate communications at https://www.nrxpharma.com.

The regulatory progress comes amid growing recognition of ketamine’s potential in treating severe mental health conditions that have proven resistant to traditional therapies. The FDA’s positive review letter represents a significant step forward in making this treatment available to patients who have limited options. The company’s work is part of broader efforts to address the mental health crisis through innovative pharmacological approaches.

This development matters because it advances a potentially life-saving treatment for patients with severe depression and suicidal ideation, conditions that represent significant public health challenges. The FDA’s engagement with the company reflects governmental priorities to accelerate treatments for serious mental illness, potentially reducing the burden of these conditions on individuals, families, and healthcare systems. The progress toward a 2026 approval timeline offers hope for patients who have exhausted conventional treatment options.

This news story relied on content distributed by InvestorBrandNetwork (IBN). Blockchain Registration, Verification & Enhancement provided by NewsRamp. The source URL for this press release is FDA Advances NRx Pharmaceuticals’ Ketamine Treatment for Severe Mental Illness.

The post FDA Advances NRx Pharmaceuticals’ Ketamine Treatment for Severe Mental Illness appeared first on citybuzz.